Applied DNA Sciences special meeting fails quorum; warrant approval delayed

BNB PLUS CORP.

Reconvened special meeting on Feb 28, 2025, had only 16,413,535 shares present, short of one-third outstanding requirement.
No action taken on proposal to approve exercise of Series C & D warrants from October 2024 offering.
Company is obligated to call another stockholder meeting to seek warrant stockholder approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.